POEMs and Tips

From Other Journals

Once-a-Day Medication for ADHD Treatment



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2003 Sep 1;68(5):956.

Attention-deficit/hyperactivity disorder (ADHD) has long been treated with the stimulant medication methylphenidate in an immediate-release formula. The disadvantage of this medication is the very short half-life and the necessity for multiple dosing during the day. This becomes an issue when the medication is used to treat school-aged children. The optimal dosing schedule is three times in a 12-hour period, which would require that the medication be administered during school hours. This may cause embarrassment for the student and also has implications with regard to administering a controlled substance during school hours. An initial attempt to create sustained-release methylphenidate was unsuccessful because the formula reduced the effectiveness of the medication. Recently, however, a new sustained-release formula has been developed. Swanson and colleagues studied the pharmacokinetics and pharmacodynamics of methylphenidate in the new sustained-released formula.

The study participants were children seven to 13 years of age who met criteria from the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) for the diagnosis of ADHD. In addition, these children were already being treated with immediate-release methylphenidate in a dosage of 5 to 15 mg two to three times per day. A university laboratory school evaluated the children multiple times on nonconsecutive days using a teachers' assessment tool. In the first phase of the study, children were given capsules containing active medication or placebo in 30-minute intervals to determine the validity of a sustained-release preparation. In the second phase, the pharmacokinetics and pharmacodynamics of a new once-a-day methylphenidate were assessed.

The first phase of the study demonstrated that the ascending dose that mirrored a sustained-release preparation was similar to the standard three-times-per-day dosage of methylphenidate. In the pharmacokinetic study of the new once-a-day formula of methylphenidate, plasma levels increased rapidly, peaking seven to nine hours after administration. The results of the pharmacodynamic studies of the new formula matched those of the three-times-per-day dosage of methylphenidate in terms of onset and duration of efficacy.

The authors conclude that the new once-a-day formula of methylphenidate has a rapid onset and long duration of efficacy after a single morning dose. This provides children with ADHD an option for once-a-day treatment of their symptoms.

Swanson J, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. February 2003;60:204–11.


Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article